The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

Pittsburgh residents will not get to vote on whether to divest from genocide in the May 20 primary election after legal ...